SLC6A2 and attention deficit-hyperactivity disorder: To our knowledge, most of the pharmacogenetic studies of SLC6A2 in ADHD have been conducted on Western populations [11,13,21], and there have been no studies on the association between the SLC6A2 -3081(A/T) polymorphism and the response to MPH treatment.